Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial
Official title:
Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients
This phase I trial studies the side effects and best dose of donor cord blood T-cells after stem cell transplant in treating patients with relapsed hematological malignancies. After umbilical cord blood transplant, stem cells are collected from the donor's cord blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by treatment. Removing the T cells and treating them in the laboratory before infusing them in the patient may also help boost the patient's immune system.
PRIMARY OBJECTIVES:
I. To evaluate the safety and maximum tolerated dose (MTD) of infusion of ex vivo expanded
cord blood T cells (CLI), in cord blood (CB) transplant recipients with relapsed
hematological malignancies.
SECONDARY OBJECTIVES:
I. To determine the complete remission rate and overall response as a result of CLI infusion.
II. To determine the effect of CLI infusion on the chimerism. III. To evaluate the incidence
rate and grade of acute graft-versus-host disease (GvHD) after CLI infusion.
IV. To determine the disease-free survival, cytopenia rate, relapse incidence after CLI
infusion.
OUTLINE: This is a dose-escalation study of ex vivo-expanded T-cells.
Patients undergo ex vivo-expanded umbilical cord blood progenitor cell donor T cell infusion
with aldesleukin 11-14 days after T-cell co-stimulation begins.
After completion of study treatment, patients are followed up for 100 days.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT05106374 -
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT05660421 -
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
|
Phase 2 | |
| Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
| Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
| Withdrawn |
NCT04127721 -
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03712878 -
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
|
Phase 2 | |
| Active, not recruiting |
NCT06062901 -
An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors
|
N/A | |
| Terminated |
NCT04081298 -
eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
|
N/A | |
| Completed |
NCT04983901 -
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
|
Phase 2 | |
| Recruiting |
NCT04188912 -
Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
|
||
| Active, not recruiting |
NCT04592250 -
Financial Toxicity in Cancer Patients
|
||
| Recruiting |
NCT05112614 -
Role of Gut Microbiome in Cancer Therapy
|
||
| Active, not recruiting |
NCT04296305 -
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
|
Phase 4 | |
| Withdrawn |
NCT04190433 -
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
|
Phase 2 | |
| Terminated |
NCT04083170 -
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
|
Phase 2 | |
| Recruiting |
NCT02464696 -
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
|
N/A | |
| Withdrawn |
NCT04820894 -
Perception of Cure Among Patients With Metastatic Cancer
|
||
| Completed |
NCT03125070 -
Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
|
Phase 3 | |
| Completed |
NCT01664910 -
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
|
Phase 1/Phase 2 |